Zyprexa Rxs Stabilize, But 2006 Gains Largely Driven By Dual-Eligible Switch
Executive Summary
Zyprexa prescription trends are showing signs of stabilization in the U.S., but rebounding sales of Lilly's top-selling drug will be challenged this year as the full-year effect of patient switches from Medicaid to Medicare Part D cycles through in the first quarter, the company said
You may also be interested in...
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4
Cymbalta “Mood” And “Pain” Claims May Include Fibromyalgia And Anxiety
Lilly is pursuing fibromyalgia and generalized anxiety disorder indications to add to the two currently approved indications for Cymbalta
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.